1. Scrip

Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV

 
• By Joseph Haas

UnitedHealthcare offers HIV-infected patients a financial incentive to switch to lower-cost therapy, including generic TDF, but analysts suspect the savings won’t be enough to encourage much switching away from Gilead’s single-tablet regimens.

Digital illustration of HIV Virus in Blood Stream in color background

[UnitedHealthCare] recently rolled out a new plan to offer financial incentives for HIV patients to switch to lower-cost therapies, but analysts have concluded that the benefits to insured patients likely won’t be enough to challenge preference for the newer single-tablet regimens offered by Gilead Sciences Inc. and ViiV Healthcare .

The My ScriptRewards program now grants patients up to $500 in debit cards if they – after consultation with a physician – switch to one of two HIV regimens – Mylan NV’s Cimduo (lamivudine/tenofovir disoproxil fumarate) plus ViiV’s Tivicay (dolutegravir) or Cimduo plus Merck & Co. Inc.’s Isentress (raltegravir)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.